目的 比較使用流式細胞儀355 nm和407 nm激光器激發Hochest33342檢測細胞凋亡。 方法 通過ATO藥物誘導急性早幼粒白血病細胞（NB4）及血清饑餓法誘導人肺癌細胞（NCl-H292）細胞凋亡，取24、48 h時間點收集細胞，進行Hoechst33342-碘化丙啶（PI）雙染，分別在配置有兩種激光器的流式細胞儀上檢測細胞凋亡。 結果 細胞經處理后24 h，355 nm激光器檢測NB4細胞凋亡率Hoechst33342+/PI-：（28.20 ± 4.80）%；NCl-H292細胞凋亡率Hoechst33342+/PI-：（22.47 ± 2.78）%。407 nm激光器檢測NB4細胞凋亡率Hoechst33342+/PI-：（25.10 ± 6.19）%。NCl-H292細胞凋亡率Hoechst33342+/PI-：20.47 ± 1.46%。處理后48 h，355 nm激光器檢測NB4細胞凋亡率Hoechst33342+/PI-：（33.60 ± 3.75）%。NCl-H292細胞凋亡率Hoechst33342+/PI-：（26.77 ± 1.16）%。407 nm激光器檢測NB4細胞凋亡率Hoechst33342+/PI-：（29.47 ± 2.33）%。NCl-H292細胞凋亡率Hoechst33342+/PI-：（31.47 ± 3.05）%。兩種細胞處理后比處理前凋亡率明顯升高，但355 nm激光器與407 nm激光器檢測的凋亡結果差異不明顯（P＞0.05）。 結論 407 nm激光器激發Hoechst33342可檢測細胞凋亡。
目的 建立急性白血病（AL）患者八色流式免疫表型分析起始管方案。 方法 用胞膜CD3（CD3）、CD19、CD10、CD34、CD45、胞漿CD79a（cCD79a）、髓過氧化物酶（MPO)和胞漿CD3（cCD3）等8種抗體建立八色流式染色方案。膜表面抗體直接染色；膜內抗體經固定破膜，再染色后上機檢測。將3個血小板減少患者骨髓標本分別進行抗體的單色染色和缺一色染色；最后對17例確診的AL初發患者標本進行檢測。 結果 用單色染色來確定染色方案中各抗體的檢測電壓及熒光補償；缺一色染色中，陽性細胞群較單色染色變化均＜10%，表明方案中的各抗體相互作用小。17例AL初發患者中，6例急性B淋巴細胞白血病原始細胞均為CD34和CD19陽性，5例cCD79a陽性和4例CD10陽性；4例急性T淋巴細胞白血病患者均為cCD3陽性；6例急性髓細胞白血病均為CD34和MPO陽性；1例B+T混合表型AL患者CD34、cCD3、CD19、cCD79a及CD10均為陽性，MPO和CD3為陰性，此檢測方案能夠確定各類AL的細胞類型。 結論 建立了AL患者八色流式免疫表型分析起始管方案，操作簡便快速，適用于臨床檢測。
ObjectiveCD44 and CD54 are two specific biomarkers of gastric cancer stem cells and were used as targets in this study. The number of CD45–CD44+CD54+ cell subsets in peripheral blood of gastric cancer patients was detected by flow cytometry. Further, we combined these results with the clinicopathological characteristics of gastric cancer patients to analyze the significance of CD45–CD44+CD54+ cell subsets.MethodsFrom December 2016 to September 2017, 38 patients with gastric cancer in gastrointestinal surgery of West China Hospital of Sichuan University were included as the study object. The content of CD45–CD44+CD54+ cell subsets in their peripheral blood was detected by flow cytometry and its clinical significance was analyzed.ResultsThe median number of CD45–CD44+CD54+ cells were 541.9/mL (71.7–8 057.0/mL) in 38 patients and 555.9/mL (71.7–8 057.0/mL) in the group of patients with R0 resection. Patients without lymph node metastasis were found to have more CD45–CD44+CD54+ cells than patients with lymph node metastasis [941.4/mL (183.5–8 057.0)/mL vs 379.3/mL (71.7–2 269.7/mL, P=0.002], and more CD45–CD44+CD54+ cells in patients with TNM stage Ⅰ–Ⅱ than in TNM stage Ⅲ–Ⅳ [858.6/mL (183.5–8 057.0/mL) vs 364.6/mL (71.7–2 269.7/mL, P=0.015]. The patients with T3–4 stages (P= 0.025), N+ stage (P=0.009) and TNM Ⅲ–Ⅳ stage (P=0.012) had low ratios of the subgroup with high number of CD45–CD44+CD54+ cells, respectively. We made a more accurate judgment of N stage and TNM stage when we combined tumor size and the number of CD45–CD44+CD54+ cells together. However, there was no significant correlation between the number of CD45–CD44+CD54+ cells and other clinicopathological features and prognosis.ConclusionsThe number of CD45–CD44+CD54+ cell subsets is correlated with tumor progression, which might be used to predict TNM stage and N stage. However, the number of patients included in this study is too small, and the clinical significance of CD45–CD44+CD54+ subsets in gastric cancer patients needs to be further demonstrated by expanding the sample size.